Ken Walsh is a Partner with Clarivate Consulting and brings with him over 20 years of experience across the life science industry with a deep focus on global pricing and market access strategy.
Ken leads engagements spanning development to commercial strategy with a focus on Europe and emerging markets: Clinical trial design strategy for HTAs, BD&L assessments and landscape analysis, MedTech reimbursement strategy and tactics, Pricing strategy and tactical tools / modelling, Mock Negotiation Workshops & Stakeholder engagement.
Ken’s industry roles were as head of pricing in GSK’s emerging markets division and as global head of pricing and market access for Sandoz Biosimilars and Oncology injectables business unit. Ken actively gives presentations at international conferences across a range of market access and public policy issues.
Ken graduated with a MA (hons) in Economics from Heriot-Watt University and an MSc in Finance from Cass Business School, London.